Janux Therapeutics Inc (NASDAQ:JANX) — Market Cap & Net Worth
Market Cap & Net Worth: Janux Therapeutics Inc (JANX)
Janux Therapeutics Inc (NASDAQ:JANX) has a market capitalization of $878.78 Million ($878.78 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9457 globally and #2629 in its home market, demonstrating a -18.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Janux Therapeutics Inc's stock price $16.44 by its total outstanding shares 60984354 (60.98 Million). Also see JANX total assets for a full breakdown of the balance sheet.
Janux Therapeutics Inc Market Cap History: 2021 to 2026
Janux Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $1.20 Billion to $1.00 Billion (-7.76% CAGR). Also see JANX operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Janux Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.03% | #268 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #990 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.05% | #158 of 263 |
Weight: Janux Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Janux Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Janux Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Janux Therapeutics Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
84.16x
Janux Therapeutics Inc's market cap is 84.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.20 Billion | $3.64 Million | -$32.56 Million | 330.83x | N/A |
| 2022 | $803.16 Million | $8.61 Million | -$54.15 Million | 93.26x | N/A |
| 2023 | $654.36 Million | $8.08 Million | -$58.29 Million | 80.96x | N/A |
| 2024 | $3.27 Billion | $10.59 Million | -$68.99 Million | 308.38x | N/A |
| 2025 | $841.58 Million | $10.00 Million | -$113.62 Million | 84.16x | N/A |
Competitor Companies of JANX by Market Capitalization
Companies near Janux Therapeutics Inc in the global market cap rankings as of September 17, 2026. Review JANX tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Janux Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Janux Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Janux Therapeutics Inc's market cap moved from $1.20 Billion to $ 1.00 Billion, with a yearly change of -7.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.00 Billion | +19.13% |
| 2025 | $841.58 Million | -74.22% |
| 2024 | $3.27 Billion | +398.97% |
| 2023 | $654.36 Million | -18.53% |
| 2022 | $803.16 Million | -33.25% |
| 2021 | $1.20 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Janux Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $878.78 Million USD |
| MoneyControl | $878.78 Million USD |
| MarketWatch | $878.78 Million USD |
| marketcap.company | $878.78 Million USD |
| Reuters | $878.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in… Read more